193 related articles for article (PubMed ID: 31342670)
1. Lower serum interleukin-22 and interleukin-35 levels are associated with disease status in neuromyelitis optica spectrum disorders.
Yang H; Han L; Zhou YJ; Ding J; Cai Y; Hong RH; Hao Y; Zhu DS; Shen XF; Guan YT
CNS Neurosci Ther; 2020 Feb; 26(2):251-259. PubMed ID: 31342670
[TBL] [Abstract][Full Text] [Related]
2. Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders.
Zhang DQ; Jia K; Wang R; Li T; Zhao N; Yang LN; Yang L
J Neuroimmunol; 2016 Apr; 293():100-104. PubMed ID: 27049569
[TBL] [Abstract][Full Text] [Related]
3. Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders.
Zhang Y; Yao XY; Gao MC; Ding J; Hong RH; Huang H; Zhuang L; Wang YG; Hao Y; Guan YT
CNS Neurosci Ther; 2018 Jan; 24(1):64-69. PubMed ID: 29110391
[TBL] [Abstract][Full Text] [Related]
4. Increased serum IL-36β and IL-36γ levels in patients with neuromyelitis optica spectrum disorders: association with disease activity.
Yang CS; Zhang QX; Deng Y; Zhou BJ; Zhang LJ; Li LM; Qi Y; Wang J; Yang L; Shi FD
BMC Neurol; 2019 Aug; 19(1):185. PubMed ID: 31382910
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity.
Yang MG; Tian S; Zhang Q; Han J; Liu C; Zhou Y; Zhu J; Jin T
Mult Scler Relat Disord; 2020 Nov; 46():102430. PubMed ID: 32853892
[TBL] [Abstract][Full Text] [Related]
6. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder.
Masuda H; Mori M; Uzawa A; Uchida T; Ohtani R; Kobayashi S; Kuwabara S
J Neurol Sci; 2018 Feb; 385():64-68. PubMed ID: 29406915
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity.
Song Y; Zhu M; Liu C; Zheng C; Zhou Y; Zhu J; Jin T
Immunobiology; 2019 May; 224(3):397-401. PubMed ID: 30852049
[TBL] [Abstract][Full Text] [Related]
9. Correlation between serum levels of endothelin-1 and disease severity in patients with neuromyelitis optica spectrum disorders.
Yi M; Liu MQ; Chou LS; Jiang SM; Zhang LJ; Huang CN; Wang N; Zhang QX; Yang L
Immunobiology; 2020 May; 225(3):151959. PubMed ID: 32517881
[TBL] [Abstract][Full Text] [Related]
10. Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder.
Wang Y; Zhou Y; Sun X; Lu T; Wei L; Fang L; Chen C; Huang Q; Hu X; Lu Z; Peng L; Qiu W
Neuroimmunomodulation; 2016; 23(5-6):352-358. PubMed ID: 28445879
[TBL] [Abstract][Full Text] [Related]
11. Low levels of vitamin D and the relationship between vitamin D and Th2 axis-related cytokines in neuromyelitis optica spectrum disorders.
Gao M; Yao X; Ding J; Hong R; Wu Y; Huang H; Zhuang L; Li Z; Wang Y; Zhang Y; Guan Y
J Clin Neurosci; 2019 Mar; 61():22-27. PubMed ID: 30692037
[TBL] [Abstract][Full Text] [Related]
12. Serum albumin level is associated with the severity of neurological dysfunction of NMOSD patients.
Yao XY; Wu YF; Gao MC; Hong RH; Ding J; Hao Y; Zhang Y; Guan YT
Mult Scler Relat Disord; 2020 Aug; 43():102130. PubMed ID: 32417662
[TBL] [Abstract][Full Text] [Related]
13. Resolution of inflammation in neuromyelitis optica spectrum disorders.
Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
[TBL] [Abstract][Full Text] [Related]
14. Plasma Homocysteine Level Is Associated with the Expanded Disability Status Scale in Neuromyelitis Optica Spectrum Disorder.
Liang J; Liu J; Fan R; Chen Z; Chen X; Tong J; Chen Y; Peng F; Jiang Y
Neuroimmunomodulation; 2019; 26(5):258-264. PubMed ID: 31655825
[TBL] [Abstract][Full Text] [Related]
15. Reduced serum IgG galactosylation is associated with increased inflammation during relapses of neuromyelitis optica spectrum disorders.
Gao S; Jiao X; Guo R; Song X; Li B; Guo L
Front Immunol; 2024; 15():1357475. PubMed ID: 38576616
[TBL] [Abstract][Full Text] [Related]
16. Association of serum Cystatin C with neuromyelitis optica spectrum disorders.
Shu Y; Zhang L; Chang Y; Li R; Sun X; Li J; Wu H; Yang Y; Peng L; Lu Z; Kermode AG; Qiu W
Eur J Neurol; 2018 Jul; 25(7):999-1002. PubMed ID: 29603501
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study.
Wang J; Cui C; Lu Y; Chang Y; Wang Y; Li R; Shan Y; Sun X; Long Y; Wang H; Wang Z; Lee M; He S; Lu Z; Qiu W; Tan S
Front Immunol; 2021; 12():720907. PubMed ID: 34421925
[TBL] [Abstract][Full Text] [Related]
18. Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders.
Du L; Chang H; Xu W; Zhang X; Yin L
Mult Scler Relat Disord; 2021 Jul; 52():102940. PubMed ID: 33930716
[TBL] [Abstract][Full Text] [Related]
19. Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders.
Fan X; Jiang Y; Han J; Liu J; Wei Y; Jiang X; Jin T
Mediators Inflamm; 2016; 2016():3678152. PubMed ID: 27057097
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
